Keyphrases
Indonesia
100%
Indonesian
37%
Transmembrane
35%
Primaquine
35%
Prostate
35%
Androgens
35%
Triple-negative Breast Cancer Cells
29%
Clinical Trials
27%
Plasma Concentration
23%
Jakarta
23%
Falciparum Malaria
22%
Cytochrome P450 2D6 (CYP2D6)
21%
Type 2 Diabetes Mellitus (T2DM)
21%
Indonesian Population
21%
Hydroxylation
21%
Pada
21%
Postmenopausal Women
21%
Randomized Controlled Trial
20%
Genotype
19%
Clinical Response
19%
High-performance Liquid Chromatography
18%
Acute Lymphoblastic Leukemia
18%
Amikacin
18%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
16%
Rifampicin
16%
Doxorubicin
16%
Randomized Clinical Trial
15%
Rat Plasma
15%
Pediatric
15%
Healthy Volunteers
15%
Human Plasma
14%
Butyrylcholinesterase (BChE)
14%
Neonate
14%
Steroid Response
14%
Mephenytoin
14%
Hematotoxicity
14%
Isoflavone Supplementation
14%
Granulocyte Colony-stimulating Factor (G-CSF)
14%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
14%
Kidney Injury molecule-1 (KIM-1)
14%
Soy Isoflavones
14%
Carbamazepine
14%
Osteopenia
14%
Plasminogen Activator inhibitor-1 (PAI-1)
14%
Clopidogrel Resistance
14%
Percutaneous Coronary Intervention
14%
Ritonavir
14%
Double-blind Randomized Controlled Trial
14%
Dari
14%
Neoadjuvant Chemotherapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Primaquine
35%
Randomized Controlled Trial
33%
Clinical Trial
31%
Normal Human
22%
Plasmodium Vivax Malaria
22%
Pharmacokinetics
21%
Triple Negative Breast Cancer
21%
Isoniazid
21%
Endophthalmitis
21%
Androgen
20%
Combination Therapy
20%
Amikacin
17%
Acute Lymphoblastic Leukemia
17%
Chemotherapy
17%
Rifampicin
16%
Doxorubicin
16%
High Performance Liquid Chromatography
15%
Mercaptopurine
15%
Drug Interaction
15%
Pseudomonas aeruginosa
14%
Ritonavir
14%
Granulocyte Colony Stimulating Factor
14%
Melatonin
14%
Blood Toxicity
14%
Clopidogrel
14%
CYP2D6
14%
Kidney Injury Molecule 1
14%
Mouth Squamous Cell Carcinoma
14%
Carbamazepine
14%
Non Insulin Dependent Diabetes Mellitus
14%
Proguanil
14%
Levofloxacin
14%
Cross-Sectional Study
13%
Decompensated Liver Cirrhosis
11%
Cisplatin
11%
Infection
11%
Side Effect
11%
Gentamicin
10%
Cycloguanil
10%
Malignant Neoplasm
10%
Creatinine
10%
Randomized Clinical Trial
9%
Placebo
9%
Bioavailability
9%
Proctitis
9%
Paclitaxel
9%
P-Glycoprotein
9%
Observational Study
9%
Plasmodium vivax
8%
Prevalence
8%